Therapies targeting PI3K/Akt signaling have demonstrated impressive anticancer activities against a broad range of human cancers [36, 37]; therefore, agents blocking CCL18-induced PI3K/Akt signaling might provide complementary effects in OSCC treatment. Here, CCL18 is linked to cancer.